1). Sherrer YS., Bloch DA., Mitchell DM., Roth SH., Wolfe F., Fries JF. Disability in rheumatoid arthritis: comparison of prognostic factors across three populations. J Rheumatol. 1987. 14:705–9.
2). Kaplan RM., Anderson JP. A general health policy model: update and applications. Health Serv Res. 1988. 23:203–35.
3). Hurst NP., Kind P., Ruta D., Hunter M., Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997. 36:551–9.
Article
4). Kim MH., Cho YS., Uhm WS., Kim S., Bae SC. Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases. Quality of Life Research. 2005. 14:1401–6.
Article
5). Fries JF., Spitz P., Kraines RG., Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980. 23:137–45.
Article
6). Torrance GW., Feeny DH., Furlong WJ., Barr RD., Zhang Y., Wang Q. Multiattribute utility function for a comprehensive health status classification system: Health Utilities Index Mark2. Med Care. 1996. 34:702–22.
7). Brenna A., Bansback N., Reynolds A., Conway P. Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford). 2004. 43:62–72.
8). Tanno M., Nakamura I., Ito K., Tanaka H., Ohta H., Kobayashi M, et al. Modelling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol. 2006. 16:77–84.
9). Linde L., SoSrensen J., OSstergaard M., HoSrslev-Pedersen K., Lund Hetland M. Health-related quality of life: validity, reliability, and responsiveness of SF-36, EQ-15D, EQ-5D, RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol. 2008. 35:1528–37.
10). Kim CG., Oh KT., Choe JU., Bae SC. Health-related quality of life in korean patients with rheumatoid arthritis. J Korean Rheum Assoc. 2002. 9:S60–72.
11). Bae SC., Cook EF., Kim SY. Psychometric evaluation of a Korean Health Assessment Questionnaire for clinical research. J Rheumatol. 1998. 25:1975–9.
12). Bansback N., Marra C., Tsuchiya A., Anis A. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum. 2007. 57:963–71.
Article
13). Ware JE., Snow KK., Kosinski M., Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA, New England Medical Center, The Health Institute. 1993.
14). Bergner M., Bobbitt RA., Carter WB., Gilson BS. The sickness impact Profile: development and final revision of a health status measure. Med Care. 1981. 19:787–805.
Article
15). Torrance GW., Thomas WH., Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res. 1972. 7:118–33.
16). Meenan RF., Gertman PM., Mason JH. Measuring health status in arthritis. The arthritis impact measurement scales. Arthritis Rheum. 1980. 23:146–52.
17). Fries JF., Spitz PW., Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol. 1982. 9:789–93.
18). Scott DL., Khoshaba B., Choy EH., Kingsley GH. Limited correlation between the Health Assessment Questionnaire (HAQ) and EuroQol in rheumatoid arthritis: questionable validity of deriving quality adjusted life years from HAQ. Ann Rheum Dis. 2007. 66:1534–7.
Article
19). Harrison MJ., Lunt M., Verstappen SM., Watson KD., Bansback NJ., Symmons DP. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. Health Qual Life Outcomes. 2010. 8:21.
Article